Palbociclib is a CDK4/6 inhibitor that slows tumour cell proliferation by halting the cell cycle.
Recommended for:
Postmenopausal women with HR+ HER2- advanced or metastatic breast cancer
Use in combination with aromatase inhibitors or fulvestrant
Prolonging progression-free survival
Hormone-resistant cancer cases
Hormone receptor-positive, HER2-negative breast cancer
Advanced or metastatic disease in postmenopausal women
To be used with hormonal therapy
Take orally once daily for 21 consecutive days, followed by a 7-day break. Use in combination with hormonal therapy. Dose adjustments are made based on patient tolerance and therapeutic response.
Contraindications:
Hypersensitivity to palbociclib
Severe hepatic impairment
Pregnancy and breastfeeding
Side Effects:
Neutropenia, anaemia
Diarrhoea, fatigue
Upper respiratory tract infections
Hair thinning, headache